Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back
Leading European HTAs Call For Further Data Collection, Responsible Pricing
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
You may also be interested in...
ASCO 2020: Roche Highlights TIGIT As Tecentriq Bags Another Approval
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
Tumor-Agnostic First In England As NICE Reverses Vitrakvi Rejection
Bayer’s “game-changing” histology-independent treatment is to be made available via the Cancer Drugs Fund.
NICE Gives Landmark Nod To Bayer's Vitrakvi
Vitrakvi is the first in a new generation of tumor-agnostic drugs to be made available on the NHS after Bayer and NICE finally reached agreement over pricing and access while more data is collected on its clinical effectiveness.